Vor Bio Appoints Adi Osovsky as General Counsel: Experienced Legal Leader to Support Growth in Autoimmune Diseases Treatment

Vor Bio has appointed Adi Osovsky, S.J.D. as General Counsel. Osovsky brings 17 years of experience in corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. She will oversee governance, compliance, and strategic transactions to support Vor Bio's growth. Osovsky joins from iTeos Therapeutics and previously held senior legal roles at Sarepta Therapeutics. She holds an LL.B. from Tel Aviv University and an LL.M. and S.J.D. in Securities Regulation from Harvard Law School.

Cambridge, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, has appointed Adi Osovsky, S.J.D., as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors.

Dr. Osovsky will oversee governance, compliance, and strategic transactions to support Vor Bio's growth. She joins from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. Prior to iTeos, she held senior legal roles at Sarepta Therapeutics, advising on corporate transactions, securities matters, and governance during a period of rapid growth and transformation.

Earlier in her career, Dr. Osovsky was an associate in the Capital Markets practice at Sullivan & Worcester LLP, where she advised biotechnology and pharmaceutical companies on corporate finance, governance, and securities regulation. She holds an LL.B. from Tel Aviv University and both an LL.M. and an S.J.D. in Securities Regulation from Harvard Law School.

"We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi’s proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadership team. Her counsel will be invaluable as we advance our late-stage clinical programs and prepare for growth."

Dr. Osovsky holds an LL.B. from Tel Aviv University and both an LL.M. and an S.J.D. in Securities Regulation from Harvard Law School. "I am thrilled to join Vor Bio at such a pivotal time," said Dr. Osovsky. "Vor Bio’s mission to transform the treatment of autoimmune diseases deeply resonates with me, and I look forward to partnering with this talented team to advance the company’s mission and enable long-term success for patients."

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information, visit [www.vorbio.com](http://www.vorbio.com).

References:
[1] https://finance.yahoo.com/news/vor-bio-appoints-adi-osovsky-120000267.html
[2] https://www.nasdaq.com/press-release/vor-bio-appoints-adi-osovsky-sjd-general-counsel-2025-09-02